Redose
MOTS-c is a short 16-amino-acid peptide encoded not in the nuclear genome but in the mitochondrial genome itself. Discovered by researchers at the University of Southern California in 2015, it belongs to a small family of mitochondrial-derived peptides (MDPs) and has attracted significant interest for its role in regulating metabolism, improving insulin sensitivity, and potentially influencing aging biology. It is not approved by the FDA or any major regulatory authority for therapeutic use and remains strictly investigational.
What is MOTS-c
MOTS-c (Mitochondrial Open reading frame of the twelve S rRNA type-c) is a 16-amino-acid peptide translated from a small open reading frame within the mitochondrial 12S ribosomal RNA gene. Its discovery broadened understanding of the mitochondrial genome: rather than only encoding structural components of the respiratory chain, mitochondrial DNA can produce bioactive signaling peptides that circulate systemically and communicate with the nucleus.
Circulating MOTS-c levels decline with age in both animals and humans, a pattern that has made it a subject of active research in longevity and metabolic medicine. Its close relative humanin and a growing list of other MDPs suggest that mitochondria act not only as cellular power plants but as endocrine-like signaling hubs.
How it works
MOTS-c exerts most of its studied effects through AMPK (AMP-activated protein kinase), a master energy-sensing enzyme. By activating AMPK, MOTS-c promotes:
- Glucose uptake in skeletal muscle, partially independent of insulin signaling
- Fatty acid oxidation, increasing the use of fat as a fuel substrate
- Suppression of the folate cycle and de novo purine synthesis, which reduces one-carbon metabolite availability and shifts cellular metabolism toward oxidative phosphorylation
- Mitochondrial biogenesis signaling, supporting mitochondrial health over time in preclinical models
MOTS-c translocates to the nucleus under metabolic stress, where it modulates gene expression related to redox balance and mitochondrial function. This nuclear-mitochondrial crosstalk is a distinctive feature that separates it from many conventional peptide drugs.
What the research says
Research into MOTS-c is early-stage. The large majority of published data comes from cell culture experiments and mouse models. Human clinical trials are very limited, and no large randomized controlled trials have been completed as of mid-2026.
Key findings from preclinical and early human research include:
| Area | Finding | Context |
|---|---|---|
| Insulin resistance | Improved glucose tolerance and reduced high-fat diet-induced insulin resistance | Mouse models |
| Exercise capacity | Enhanced running endurance and skeletal muscle adaptation | Mouse studies |
| Aging | Declining levels in older adults; exogenous MOTS-c partially reversed age-related metabolic decline in aged mice | Animal data |
| Obesity | Reduced adiposity and improved lipid profiles with repeated administration | Preclinical |
| Human pharmacokinetics | Small studies in healthy volunteers suggest tolerability, but pharmacokinetic parameters (half-life, volume of distribution) are not robustly characterized | Limited human data |
These results are promising at the preclinical level, but animal-to-human translation is never guaranteed. No regulatory body has reviewed or approved MOTS-c for any indication, and independent replication of early findings is ongoing.
Typical dosing
Dosing information for MOTS-c is based on self-reported protocols in online research communities and extrapolation from animal studies. There is no clinically validated human dosing regimen.
Ranges commonly reported in research contexts include:
- Dose per injection: 5-10 mg
- Frequency: 2-3 times per week, though some protocols describe daily use
- Duration: Cycles of 4-12 weeks are common in reported protocols
- Route: Subcutaneous injection is most frequently described; intravenous use appears in some preclinical studies
Because MOTS-c is a mitochondria-derived peptide with systemic metabolic effects, dose-response relationships in humans are not well characterized. Starting at the lower end of any reported range and monitoring response is the cautious approach. Always consult a qualified healthcare provider before beginning any peptide protocol.
If you are preparing a lyophilized peptide, the reconstitution guide covers sterile technique and concentration calculations. For rotating injection sites safely, see the injection site rotation guide.
Side effects and safety
MOTS-c has generally been well tolerated in the studies conducted to date, but the safety database in humans is thin. Reported and theoretical considerations include:
- Injection site reactions: Redness, swelling, or mild discomfort at the subcutaneous injection site are possible, as with any injectable compound
- Hypoglycemia risk: Given its effect on glucose uptake and insulin sensitization, there is a theoretical risk of low blood sugar, particularly in people who use insulin or other glucose-lowering medications
- Unknown long-term effects: No long-duration human safety studies have been completed
- Drug interactions: Interactions with metabolic medications (metformin, GLP-1 agonists, insulin) have not been formally studied
MOTS-c is not a controlled substance in most jurisdictions, but its legal status as a research compound means it is not subject to the manufacturing quality controls applied to approved drugs. Purity and concentration from commercial sources can vary considerably.
Tracking MOTS-c with Redose
Logging MOTS-c doses consistently is the only way to draw meaningful personal observations about effects on energy, body composition, or metabolic markers. The Redose app (available at /#download) lets you build a custom MOTS-c protocol, set dose reminders, rotate injection sites automatically, and track a running inventory so you know exactly how many vials remain in a cycle.
The free calculators at /calculators handle reconstitution math for you: enter your vial size and BAC water volume, and the app returns the exact draw volume per dose, removing the arithmetic error that trips up many researchers.
This profile is educational information, not medical advice. Talk to a qualified healthcare provider before starting any protocol.